

Market Announcement

26 September 2023

Anatara Lifesciences Ltd (ASX: ANR) – Trading Halt

Description

The securities of Anatara Lifesciences Ltd ('ANR') will be placed in trading halt at the request of ANR, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 28 September 2023 or when the announcement is released to the market.

Issued by

Lisa Banh

Senior Adviser, Listings Compliance

ASX Release

Ms Lisa Banh
Senior Advisor, Listings Compliance
ASX Compliance Pty Limited
20 Bridge Street
Sydney NSW 2000

Email tradinghaltssydney@asx.com.au

Dear Lisa,

Request for Trading Halt

MELBOURNE, 26 September 2023: Anatara Lifesciences Limited (ASX: ANR) ("**Anatara**" or "**Company**") requests an immediate trading halt be granted by ASX Limited in respect of its shares from trading on Tuesday 26 September 2023.

The trading halt is requested pending an announcement by Anatara in relation to an update on the GaRP Irritable Bowel Syndrome trial results (**GaRP Trial**).

In accordance with ASX Listing Rule 17.1, Anatara provides the following information:

- (a) the trading halt is necessary for Anatara to make an announcement to the market in relation to the GaRP Trial;
- (b) the trading halt should remain in place until the commencement of trading on Thursday 28 September 2023 unless, before that time, it makes an announcement in relation to the GaRP Trial or requests that the trading halt be lifted;
- (c) Anatara is not aware of any reason why the trading halt should not be granted; and
- (d) Anatara is not aware of any other information necessary to inform the market about the trading halt.

Yours sincerely



Stephen Denaro
Company Secretary
Anatara Lifesciences Limited

--Ends--

Released with authority of the Board.